SLC44A2 and colorectal carcinoma: The results showed that SLC44A2 expression is positively correlated with resistance to 5-Fluorouracil (5-FU) but negatively correlated with resistance to Cetuximab (Fig. S6A), suggesting that SLC44A2 could serve as a biomarker for predicting drug sensitivity to 5-FU and Cetuximab in CRC treatment.